Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Cost of Revenue (2016 - 2026)

Heron Therapeutics filings provide 11 years of Cost of Revenue readings, the most recent being $10.6 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue fell 13.59% to $10.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $43.5 million, a 6.27% decrease, with the full-year FY2025 number at $41.3 million, down 12.19% from a year prior.
  • Cost of Revenue hit $10.6 million in Q1 2026 for Heron Therapeutics, down from $11.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $21.2 million in Q2 2023 to a low of $8.4 million in Q1 2024.
  • Median Cost of Revenue over the past 5 years was $11.9 million (2025), compared with a mean of $13.2 million.
  • Biggest five-year swings in Cost of Revenue: plummeted 65.88% in 2022 and later skyrocketed 48.43% in 2023.
  • Heron Therapeutics' Cost of Revenue stood at $17.8 million in 2022, then tumbled by 44.39% to $9.9 million in 2023, then rose by 11.86% to $11.1 million in 2024, then rose by 0.56% to $11.1 million in 2025, then dropped by 4.33% to $10.6 million in 2026.
  • The last three reported values for Cost of Revenue were $10.6 million (Q1 2026), $11.1 million (Q4 2025), and $11.9 million (Q3 2025) per Business Quant data.